Sam Waksal, the former chief executive of ImClone Systems
The center now houses the research activities of ImClone Systems
, a wholly owned subsidiary of Lilly (Lilly acquired ImClone in 2008) along with certain rights to already-marketed Erbitux and ImClone's pipeline of oncology biologics.
in pretax charges related to the acquisition of ImClone Systems
Inc., in rejecting a $4.4 billion takeover bid by Bristol-Myers Squibb Co., reasserted its rights to an experimental cancer drug pivotal to the company's future value.
Patients with advanced colorectal cancer who do not have mutant forms of the gene KRAS in their tumors are most likely to benefit from the monoclonal antibody cetuximab (Erbitux[R], ImClone Systems
Inc.) and chemotherapy, compared to patients who have tumors that contain a mutated form of the gene, according to a new study presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL (Van Cutsem et al., 2008).
On October 31, 2001, Imclone Systems
requested the government to review Erbitux, the company's new cancer drug.
Incorporated (NASDAQ: IMCL), has seen global net sales of Erbitux for the fourth quarter of 2007 increase to $371 million, compared with $293 million in the fourth quarter of 2006, up 27%.
Repligen Corporation (Waltham, MA) has reached a settlement with ImClone Systems
in the lawsuit against ImClone for infringement of United States Patent 4,663,281 based on ImClone's manufacture and sale of Erbitux.
The conglomerate has long wanted to sell Kraft, but its plans were put on hold after its Philip Morris unit became embroiled in tobacco litigation.* Carl Icahn won his battle to shake up the management of ImClone Systems
, a biomedical company, when it appointed him chairman and sacked its interim chief executive.
Fischer has resigned as interim chief executive officer and as a member of the ImClone Systems
board of directors, effective Oct.
TheraCIM is an antibody therapy, which has a mechanism of action that is similar to ImClone Systems
Inc.'s Erbitux cancer drug.
28, 2001, the day Stewart sold ImClone Systems
shares based on inside information, and slid to $10 by June 4, 2003, the day of her indictment.